Research AREA: Targeted Delivery of CRISPR-Cas System and Cell/Immunotherapies
The Arias Lab was established in 2022 under the leadership of Dr. Jonathan Arias. It is one of six inaugural research groups comprising the EMBL Partnership Institute at the Vilnius University Life Sciences Center. The Partnership is centered on developing novel genome editing technologies through in vivo and in vitro research.
Regenerative medicine - The use of human induced Pluripotent Stem (iPS) cells for the creation of adult cell types has revolutionized our understanding of developmental biology, and it is prone to drive the next generation of cell-based therapeutics. It is remarkable as it can provide new therapeutic opportunities for a wide range of human diseases. Today, Genome Engineering synergizes with Regenerative Medicine allowing us to confer novel therapeutic functions to cells, yielding "smart-therapeutics". Similarly, Genome Engineering allows us correcting deleterious mutations within our genomes both in vivo and ex vivo.
To fulfill this potential, the Arias lab engineers human iPS cells utilizing cutting-edge nucleases for the creation of cell-based therapeutics with clinical translation potential. This approach allows us to manufacture cells ex vivo and therefore we can introduce therapeutic functions in a reliable manner and perform extensive quality control. Our technologies and expertise include precise genome engineering, lineage-specific differentiation and AI driven biosciences.
We are an inter-disciplinary and international team glad to establish collaborations across the globe to achieve our vision. We invite you to follow us or join us as we pursue the next generation therapeutics!
Learn more about us at Webpage of Group
Contact:
Jonathan Arias, PhD, Group Leader
LSC-EMBL Institute for Genome Editing Technologies
Vilnius University Life Science Center
7 Saulėtekio Ave, LT-10257 Vilnius, Lithuania
E: